nifedipine has been researched along with Migraine Disorders in 23 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ninety patients, 50 males and 40 females, and their ages ranged between 42 and 70 years, with severe hypertension were treated by either sublingual verapamil tablets 40 mg (30 patients) or 80 mg (30 patients) or sublingual nifedipine capsules 10 mg (30 patients)." | 7.70 | Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine. ( Al-Waili, NS; Hasan, NA, 1999) |
| "A 39-year-old woman suffering from migraine took two suppositories of an ergotamine-containing proprietary drug (Cafergot, containing 2 mg ergotamine tartrate) for the first time again after an abstinence of two years." | 5.28 | [Extremity-threatening ischemia in ergotism. Successful treatment with the intra-arterial administration of nifedipine]. ( Brandt, J; Ernst, R; Mumme, A; Schäfer, K; Zumtobel, V, 1991) |
| "Flunarizine's effect in migraine probably involves monoamine mechanisms which bear no relation to calcium." | 3.77 | [Calcium channel blockers and prevention of migraine]. ( Montastruc, JL; Senard, JM, 1992) |
| "Ninety patients, 50 males and 40 females, and their ages ranged between 42 and 70 years, with severe hypertension were treated by either sublingual verapamil tablets 40 mg (30 patients) or 80 mg (30 patients) or sublingual nifedipine capsules 10 mg (30 patients)." | 3.70 | Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine. ( Al-Waili, NS; Hasan, NA, 1999) |
| "Nifedipine is a useful agent for the management of migraine as it reduces frequency and severity of pain but the drug cannot be recommended for tension headache." | 2.68 | Nifedipine in migraine and tension headache: a randomised double blind crossover study. ( Ahuja, RC; Garg, RK; Nag, D; Shukla, R, 1995) |
| "Efficacy in migraine prophylaxis has been claimed for drugs belonging to all three classes of calcium channel blockers (nifedipine-like, verapamil-like, and flunarizine-like), but the extent and quality of the evidence varies, and a comparison of efficacy between different calcium channel blockers has not been reported." | 2.67 | Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. ( Lamsudin, R; Sadjimin, T, 1993) |
| "Patients with migraine with aura treated each of six acute attacks with either nifedipine or vehicle administered in double-blind, randomized form." | 2.67 | A double-blind controlled study of nifedipine as an abortive treatment in acute attacks of migraine with aura. ( Hoffert, MJ; Kanter, R; Scholz, MJ, 1992) |
| "Nifedipine was of no value in the prophylaxis of migraine." | 2.67 | Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. ( Diener, HC; Gerber, WD; Niederberger, U; Scholz, E, 1991) |
| "Twenty-four patients with classic migraine attacks were treated with either nifedipine or placebo for up to 12 weeks." | 2.66 | Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. ( Marek, K; McArthur, J; McArthur, JC; Peroutka, SJ; Pestronk, A, 1989) |
| "At baseline, migraine patients had significantly higher VEP amplitudes and longer latencies than did a group of 87 healthy control subjects." | 2.66 | Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. ( Bille, A; Dichgans, J; Diener, HC; Gerber, WD; Jäck, A; Niederberger, U; Scholz, E, 1989) |
| "Nifedipine was effective in only 30% of patients (6/20)." | 2.66 | Nifedipine versus propranolol for the initial prophylaxis of migraine. ( Albers, GW; Hamik, A; Peroutka, SJ; Simon, LT, 1989) |
| "In the therapy of acute cerebral ischemia the therapeutic efficacy of nimodipine administered orally is not therapeutically proved until now; the intravenous administration of nimodipine offers the risk of acute hypotensive reactions." | 2.38 | [Calcium channel blockers in therapy of neurologic diseases]. ( Wessely, P; Wöber-Bingöl, C, 1993) |
| "Migraine is one of the risk factor for ischemic stroke." | 1.37 | Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity. ( Iizuka, R; Ishii, M; Kiuchi, Y; Mori, Y; Shimizu, S, 2011) |
| "A 39-year-old woman suffering from migraine took two suppositories of an ergotamine-containing proprietary drug (Cafergot, containing 2 mg ergotamine tartrate) for the first time again after an abstinence of two years." | 1.28 | [Extremity-threatening ischemia in ergotism. Successful treatment with the intra-arterial administration of nifedipine]. ( Brandt, J; Ernst, R; Mumme, A; Schäfer, K; Zumtobel, V, 1991) |
| "It is postulated that, in migraine, calcium entry blockers may prevent exaggerated responses to catecholaminergic stimulation." | 1.27 | Pupillary and vascular effects of calcium antagonists in migraine. ( Boccuni, M; Cangi, F; Fanciullacci, M; Fusco, BM; Gatto, G; Marabini, S; Pietrini, U, 1985) |
| "Fifteen women regularly suffering from migraine during the menstrual period reported increased headache after intake of the drug." | 1.26 | Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea. ( Andersson, KE; Sandahl, B; Ulmsten, U, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (60.87) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M | 1 |
| Iizuka, R | 1 |
| Kiuchi, Y | 1 |
| Mori, Y | 1 |
| Shimizu, S | 1 |
| Kahan, A | 1 |
| Weber, S | 1 |
| Amor, B | 1 |
| Guerin, F | 1 |
| Degeorges, M | 1 |
| Meyer, JS | 1 |
| Hardenberg, J | 1 |
| Peroutka, SJ | 3 |
| Miller, FW | 1 |
| Santoro, TJ | 1 |
| Wessely, P | 1 |
| Wöber-Bingöl, C | 1 |
| Lamsudin, R | 1 |
| Sadjimin, T | 1 |
| Shukla, R | 1 |
| Garg, RK | 1 |
| Nag, D | 1 |
| Ahuja, RC | 1 |
| Al-Waili, NS | 1 |
| Hasan, NA | 1 |
| Sandahl, B | 1 |
| Ulmsten, U | 1 |
| Andersson, KE | 1 |
| Montastruc, JL | 1 |
| Senard, JM | 1 |
| Hoffert, MJ | 1 |
| Scholz, MJ | 1 |
| Kanter, R | 1 |
| Mumme, A | 1 |
| Ernst, R | 1 |
| Brandt, J | 1 |
| Schäfer, K | 1 |
| Zumtobel, V | 1 |
| Gerber, WD | 2 |
| Diener, HC | 2 |
| Scholz, E | 2 |
| Niederberger, U | 2 |
| Greenberg, DA | 1 |
| Mayerhofer, S | 1 |
| McArthur, JC | 1 |
| Marek, K | 1 |
| Pestronk, A | 1 |
| McArthur, J | 1 |
| Dichgans, J | 1 |
| Jäck, A | 1 |
| Bille, A | 1 |
| Albers, GW | 1 |
| Simon, LT | 1 |
| Hamik, A | 1 |
| Goldner, JA | 1 |
| Levitt, LP | 1 |
| Solomon, GD | 1 |
| Fournier, JA | 1 |
| Fernández-Cortacero, JA | 1 |
| Granado, C | 1 |
| Gascón, D | 1 |
| Fanciullacci, M | 1 |
| Boccuni, M | 1 |
| Pietrini, U | 1 |
| Cangi, F | 1 |
| Gatto, G | 1 |
| Marabini, S | 1 |
| Fusco, BM | 1 |
4 reviews available for nifedipine and Migraine Disorders
| Article | Year |
|---|---|
[Calcium channel blockers in therapy of neurologic diseases].
Topics: Brain Ischemia; Calcium Channel Blockers; Cluster Headache; Flunarizine; Humans; Migraine Disorders; | 1993 |
[Calcium channel blockers and prevention of migraine].
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Diltiazem; Flunarizine; Humans; Migraine Diso | 1992 |
Calcium channel antagonists and the treatment of migraine.
Topics: Calcium; Calcium Channel Blockers; Cinnarizine; Diltiazem; Flunarizine; Humans; Ion Channels; Kineti | 1986 |
Comparative efficacy of calcium antagonist drugs in the prophylaxis of migraine.
Topics: Calcium Channel Blockers; Cinnarizine; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Flu | 1985 |
12 trials available for nifedipine and Migraine Disorders
| Article | Year |
|---|---|
Nifedipine in the treatment of migraine in patients with Raynaud's phenomenon.
Topics: Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Migraine Disorders; Nifedipine; Prospec | 1983 |
Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches.
Topics: Adult; Calcium Channel Blockers; Cerebrovascular Circulation; Clinical Trials as Topic; Cluster Head | 1983 |
The pharmacology of calcium channel antagonists: a novel class of anti-migraine agents?
Topics: Calcium Channel Blockers; Cerebrovascular Circulation; Clinical Trials as Topic; Cyproheptadine; Dil | 1983 |
Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine.
Topics: Adolescent; Adult; Double-Blind Method; Female; Flunarizine; Humans; Male; Middle Aged; Migraine Dis | 1993 |
Nifedipine in migraine and tension headache: a randomised double blind crossover study.
Topics: Adult; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Drug Administration Schedu | 1995 |
[Calcium channel blockers and prevention of migraine].
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Diltiazem; Flunarizine; Humans; Migraine Diso | 1992 |
A double-blind controlled study of nifedipine as an abortive treatment in acute attacks of migraine with aura.
Topics: Acute Disease; Adult; Double-Blind Method; Humans; Middle Aged; Migraine Disorders; Nifedipine; Sens | 1992 |
Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Female; Follow-Up S | 1991 |
Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Migraine Disorders; Nifedipine; Placebos | 1989 |
Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Evoked Potentials, Visual; Female; Humans; Mal | 1989 |
Nifedipine versus propranolol for the initial prophylaxis of migraine.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Migraine Disorders; Nifedipine; | 1989 |
Comparative efficacy of calcium antagonist drugs in the prophylaxis of migraine.
Topics: Calcium Channel Blockers; Cinnarizine; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Flu | 1985 |
9 other studies available for nifedipine and Migraine Disorders
| Article | Year |
|---|---|
Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity.
Topics: Animals; Benzamides; Calcium; Calcium Channel Blockers; Cell Death; Cells, Cultured; HEK293 Cells; H | 2011 |
Nifedipine in the treatment of migraine headache and amaurosis fugax in patients with systemic lupus erythematosus.
Topics: Adult; Blindness; Female; Humans; Lupus Erythematosus, Systemic; Male; Migraine Disorders; Nifedipin | 1984 |
Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine.
Topics: Administration, Sublingual; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Female; Headache; | 1999 |
Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea.
Topics: Adolescent; Adult; Dysmenorrhea; Evaluation Studies as Topic; Female; Humans; Migraine Disorders; Ni | 1979 |
[Extremity-threatening ischemia in ergotism. Successful treatment with the intra-arterial administration of nifedipine].
Topics: Acute Disease; Adult; Arm; Caffeine; Drug Combinations; Ergotamine; Ergotism; Female; Humans; Infusi | 1991 |
[Mechanism of action of calcium antagonists in the treatment of vascular diseases].
Topics: Arterial Occlusive Diseases; Calcium; Calcium Channel Blockers; Cerebrovascular Circulation; Flunari | 1986 |
Treatment of complicated migraine with sublingual nifedipine.
Topics: Administration, Sublingual; Adolescent; Electroencephalography; Female; Humans; Migraine Disorders; | 1987 |
Familial migraine and coronary artery spasm in two siblings.
Topics: Angiography; Cardiac Catheterization; Coronary Vasospasm; Electrocardiography; Female; Hemodynamics; | 1986 |
Pupillary and vascular effects of calcium antagonists in migraine.
Topics: Blood Pressure; Calcium Channel Blockers; Cinnarizine; Flunarizine; Humans; Migraine Disorders; Nife | 1985 |